This HTML5 document contains 56 embedded RDF statements represented using HTML+Microdata notation.

The embedded RDF content will be recognized by any processor of HTML5 Microdata.

Namespace Prefixes

PrefixIRI
n2http://linked.opendata.cz/resource/drugbank/drug/
dctermshttp://purl.org/dc/terms/
n13http://linked.opendata.cz/resource/mesh/concept/
n9http://linked.opendata.cz/resource/drugbank/mixture/
n8http://bio2rdf.org/drugbank:
n11http://linked.opendata.cz/resource/drugbank/drug/DB08797/identifier/wikipedia/
admshttp://www.w3.org/ns/adms#
n14http://wifo5-03.informatik.uni-mannheim.de/drugbank/resource/drugs/
rdfhttp://www.w3.org/1999/02/22-rdf-syntax-ns#
owlhttp://www.w3.org/2002/07/owl#
n12http://linked.opendata.cz/ontology/mesh/
n3http://linked.opendata.cz/ontology/drugbank/
n4http://linked.opendata.cz/resource/drugbank/property/
xsdhhttp://www.w3.org/2001/XMLSchema#
n15http://linked.opendata.cz/resource/drugbank/drug/DB08797/identifier/drugbank/
n6http://linked.opendata.cz/resource/atc/
n5http://linked.opendata.cz/ontology/sukl/drug/

Statements

Subject Item
n2:DB08797
rdf:type
n3:Drug
n3:description
Salicylamide is the common name for the substance o-hydroxybenzamide, or amide of salicyl. Salicylamide is a non-prescription drug with analgesic and antipyretic properties. Its medicinal uses are similar to those of aspirin. Salicylamide is used in combination with both aspirin and caffeine in the over-the-counter pain remedies
n3:group
approved
owl:sameAs
n8:DB08797 n14:DB08797
dcterms:title
Salicylamide
adms:identifier
n11:Salicylamide n15:DB08797
n3:synonym
2-Carbamoylphenol 2-Carboxamidophenol Salicylic acid amide 2-Hydroxybenzamide Salicilamida o-hydroxybenzamide Salicylamidum OHB
n3:toxicity
Oral, rat LD50: 1890 mg/kg
n3:mixture
n9:271B54D3-363D-11E5-9242-09173F13E4C5 n9:271B54D4-363D-11E5-9242-09173F13E4C5
n3:synthesisReference
Elijah J. Gold, Esther Babad, Lydia Peer, Wei K. Chang, "Preparation of (-)-5-(beta)-1-hydroxy-2-((beta)-1-methyl-3-phenylpropyl)aminoethyl) salicylamide." U.S. Patent US4658060, issued November, 1979.
n12:hasConcept
n13:M0097881
n3:IUPAC-Name
n4:271B54D9-363D-11E5-9242-09173F13E4C5
n3:InChI
n4:271B54DF-363D-11E5-9242-09173F13E4C5
n3:Molecular-Formula
n4:271B54DE-363D-11E5-9242-09173F13E4C5
n3:Molecular-Weight
n4:271B54DB-363D-11E5-9242-09173F13E4C5
n3:Monoisotopic-Weight
n4:271B54DC-363D-11E5-9242-09173F13E4C5
n3:SMILES
n4:271B54DD-363D-11E5-9242-09173F13E4C5
n3:Water-Solubility
n4:271B54EF-363D-11E5-9242-09173F13E4C5 n4:271B54D7-363D-11E5-9242-09173F13E4C5
n3:logP
n4:271B54F2-363D-11E5-9242-09173F13E4C5 n4:271B54D5-363D-11E5-9242-09173F13E4C5 n4:271B54D8-363D-11E5-9242-09173F13E4C5
n3:logS
n4:271B54D6-363D-11E5-9242-09173F13E4C5
n3:pKa
n4:271B54F3-363D-11E5-9242-09173F13E4C5
n5:hasATCCode
n6:N02BA05
n3:H-Bond-Acceptor-Count
n4:271B54E5-363D-11E5-9242-09173F13E4C5
n3:H-Bond-Donor-Count
n4:271B54E6-363D-11E5-9242-09173F13E4C5
n3:InChIKey
n4:271B54E0-363D-11E5-9242-09173F13E4C5
n3:Polar-Surface-Area--PSA-
n4:271B54E1-363D-11E5-9242-09173F13E4C5
n3:Polarizability
n4:271B54E3-363D-11E5-9242-09173F13E4C5
n3:Refractivity
n4:271B54E2-363D-11E5-9242-09173F13E4C5
n3:Rotatable-Bond-Count
n4:271B54E4-363D-11E5-9242-09173F13E4C5
n3:affectedOrganism
Humans and other mammals
n3:casRegistryNumber
65-45-2
n3:category
n3:Bioavailability
n4:271B54EB-363D-11E5-9242-09173F13E4C5
n3:Boiling-Point
n4:271B54F1-363D-11E5-9242-09173F13E4C5
n3:Ghose-Filter
n4:271B54ED-363D-11E5-9242-09173F13E4C5
n3:MDDR-Like-Rule
n4:271B54EE-363D-11E5-9242-09173F13E4C5
n3:Melting-Point
n4:271B54F0-363D-11E5-9242-09173F13E4C5
n3:Number-of-Rings
n4:271B54EA-363D-11E5-9242-09173F13E4C5
n3:Physiological-Charge
n4:271B54E9-363D-11E5-9242-09173F13E4C5
n3:Rule-of-Five
n4:271B54EC-363D-11E5-9242-09173F13E4C5
n3:Traditional-IUPAC-Name
n4:271B54DA-363D-11E5-9242-09173F13E4C5
n3:pKa--strongest-acidic-
n4:271B54E7-363D-11E5-9242-09173F13E4C5
n3:pKa--strongest-basic-
n4:271B54E8-363D-11E5-9242-09173F13E4C5